GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Illumina Inc (XTER:ILU) » Definitions » Cyclically Adjusted Price-to-FCF

Illumina (XTER:ILU) Cyclically Adjusted Price-to-FCF : 16.60 (As of Jun. 05, 2025)


View and export this data going back to 2000. Start your Free Trial

What is Illumina Cyclically Adjusted Price-to-FCF?

As of today (2025-06-05), Illumina's current share price is €73.22. Illumina's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 was €4.41. Illumina's Cyclically Adjusted Price-to-FCF for today is 16.60.

The historical rank and industry rank for Illumina's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

XTER:ILU' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 14.86   Med: 88.04   Max: 186.44
Current: 17.1

During the past years, Illumina's highest Cyclically Adjusted Price-to-FCF was 186.44. The lowest was 14.86. And the median was 88.04.

XTER:ILU's Cyclically Adjusted Price-to-FCF is ranked better than
71.21% of 66 companies
in the Medical Diagnostics & Research industry
Industry Median: 27.595 vs XTER:ILU: 17.10

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Illumina's adjusted free cash flow per share data for the three months ended in Mar. 2025 was €1.169. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is €4.41 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Illumina Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Illumina's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Illumina Cyclically Adjusted Price-to-FCF Chart

Illumina Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 91.42 88.09 45.35 30.94 28.89

Illumina Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 29.90 23.80 29.12 28.89 16.58

Competitive Comparison of Illumina's Cyclically Adjusted Price-to-FCF

For the Diagnostics & Research subindustry, Illumina's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Illumina's Cyclically Adjusted Price-to-FCF Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Illumina's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Illumina's Cyclically Adjusted Price-to-FCF falls into.


;
;

Illumina Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Illumina's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=73.22/4.41
=16.60

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Illumina's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Illumina's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=1.169/134.9266*134.9266
=1.169

Current CPI (Mar. 2025) = 134.9266.

Illumina Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 0.776 100.684 1.040
201509 0.902 100.392 1.212
201512 2.046 99.792 2.766
201603 0.279 100.470 0.375
201606 1.046 101.688 1.388
201609 0.650 101.861 0.861
201612 1.153 101.863 1.527
201703 0.541 102.862 0.710
201706 0.660 103.349 0.862
201709 0.856 104.136 1.109
201712 1.245 104.011 1.615
201803 0.904 105.290 1.158
201806 1.261 106.317 1.600
201809 1.311 106.507 1.661
201812 1.359 105.998 1.730
201903 0.843 107.251 1.061
201906 0.570 108.070 0.712
201909 1.337 108.329 1.665
201912 2.332 108.420 2.902
202003 1.474 108.902 1.826
202006 1.206 108.767 1.496
202009 0.602 109.815 0.740
202012 1.911 109.897 2.346
202103 1.371 111.754 1.655
202106 1.180 114.631 1.389
202109 -1.800 115.734 -2.098
202112 1.195 117.630 1.371
202203 0.634 121.301 0.705
202206 0.325 125.017 0.351
202209 -1.917 125.227 -2.065
202212 1.437 125.222 1.548
202303 -0.254 127.348 -0.269
202306 0.339 128.729 0.355
202309 0.563 129.860 0.585
202312 1.004 129.419 1.047
202403 0.237 131.776 0.243
202406 0.286 132.554 0.291
202409 1.599 133.029 1.622
202412 2.012 133.157 2.039
202503 1.169 134.927 1.169

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Illumina  (XTER:ILU) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Illumina Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Illumina's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Illumina Business Description

Address
5200 Illumina Way, San Diego, CA, USA, 92122
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Illumina Headlines

No Headlines